Pathobiotek sells non-core businesses to attract takeover bids
This article was originally published in Clinica
Executive Summary
Pathobiotek Diagnostics, a US company developing diagnostic tests for multiple sclerosis and other immune disorders, is to abandon the strategy of buying non-core businesses. It has tentatively sold an e-commerce business, as well as a recently acquired retail cellular phone chain, which it purchased in May.